Interviewed Thought Leaders Expect Dalcetrapib and Anacetrapib to Deliver Improvements to Mortality and Cardiovascular Morbidity over Zetia, the Sales-Leading Statin Add-on/Alternative Agent for Dyslipidemia

BURLINGTON, Mass.--(BUSINESS WIRE)--Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. primary care physicians (PCPs) and managed care organization (MCO) pharmacy directors agree that improved mortality and morbidity are two of the attributes that most influence their decisions regarding prescribing and formulary status determinations, respectively, in statin add-on/alternative therapies for the treatment

Feed Date: 
February 22, 2012